VP Strategic Alliances and Operations, Amathus
Dr. Lamb joined Amathus in July 2021 as VP Strategic Alliances and Operations to lead the Merck collaboration and support the overall operational success of the team’s scientific achievements. She brings over 20 years of experience across academia, pharma and biotech that includes, technology transfer, managing multi-program strategic alliances, deal diligence and program management.
Before joining Amathus, Kim was Executive Director at AGTC where she coordinated diligence and business operation as well as managed strategic collaborations for ophthalmology and otology gene therapy programs. Prior to AGTC she established contracting capabilities for Epizyme and expanded her role into alliance management for preclinical, clinical and diagnostic strategic collaborations. She also brings experience in contract negotiations and intellectual property strategy gained while working for Merck and technology transfer offices at Beth Israel Deaconess Medical Center and University of Nebraska Medical Center, where she earned her doctorate in cell and molecular biology.
Related posts:
Year in Review: Highlights from 2023
by Charles Litton, UNeMed | December 22, 2023 It’s that time again where we look back at the year that was 2023. In keeping with tradition, here’s a look at some of the more popular and important stories, events and happenings during the previous year: 1. Boot Camp When the Tech Transfer Boot Camp returned …
UNeMed Board expands, adds expertise from Boston and San Diego
OMAHA, Nebraska (November 17, 2023)—UNeMed announced today that Michael Bishop, PhD, and Kimberly Lamb, PhD, have joined its Board of Directors. “When the topic of new Directors came up,” UNeMed Chairperson Anne Barnes said, “we knew it was important for us add expertise from the strongest biotechnology clusters in the world and we couldn’t be …